The Effects of Protein Supplementation With or Without Urolithin A During Single-leg Immobilization

Healthy Clinical Trial

Official title:

Comparison of High-protein Formulation With/Without Urolithin a During a Unilateral Knee Immobilization: a Pilot Proof-of-concept Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05814705
• Other study ID #: 13783
• Secondary ID: ISRCTN20052152
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2023
• Est. completion date: September 30, 2024

Study information

• Verified date: October 2023
• Source: McMaster University
• Contact: Brad Currier
• Phone: 9055259140
• Email: currierb[@]mcmaster.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are times in life when people cannot use their muscles, such as during illness or injury. Muscle and mitochondria (the 'energy factory' in cells) health decline very quickly when people cannot use their muscles, but certain foods can help reduce these declines. Recent research suggests that Urolithin A, which is a natural compound that can be produced after eating pomegranates, nuts, and berries, improves muscle health. In this study, the investigators aim to investigate if a protein beverage (standard care during disuse) with or without Urolithin A can reduce or prevent the loss of muscle health while wearing a knee brace (muscle disuse).

Description:

After participants provide informed consent to participate and are deemed eligible for the study (Day 0), participants will sequentially complete the three phases of this study:

1. RUN-IN phase: participants continue habitual lifestyle (Day 7-Day 14 [1 week])

2. IMMOBILIZATION phase: participants undergo 2 weeks of unilateral knee immobilization (Day 14-Day 28 [2 weeks])

3. RECOVERY phase: participants return to habitual lifestyle (Day 28-Day 35 [1 week])

Participants will consume their randomly assigned supplement daily during all three phases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: September 30, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

1. Men aged 18-30 years

2. Healthy, non-smoking

3. BMI between 20 and 30 kg/m^2

4. No orthopedic issues that would preclude participation in the knee bracing protocol

5. Not taking any medication or with any medical condition that, in the opinion of the investigators, would compromise the study outcome or the safety of the research participant

6. Provide informed consent

7. Understand COVID-19 risks and procedures for in person research and sign Information Letter: COVID-19 Risks and Procedures for In-Person Research at McMaster University

Exclusion Criteria:

1. Subject has any concurrent medical, orthopedic, or psychiatric requirements that, in the opinion of the investigators, would compromise their ability to comply with the study requirements

2. Clinically significant abnormal laboratory results at screening

3. Participation in a clinical research trial within 30 days before randomization

4. Allergy or sensitivity to study ingredients

5. Individuals who are cognitively impaired and/or who are unable to give informed consent

6. Any other condition that, in the opinion of the investigators, may adversely affect the subject's ability to complete the study or its measures or may pose a significant risk to the subject

7. Any cachexia-related condition or any genetic muscle diseases or disorders

8. Current gastrointestinal condition that could interfere with the study (e.g., IBS/IBD [irritable bowel syndrome/inflammatory bowel disease], diarrhea, acid reflux disease, dysphagia, etc.)

9. Excessive alcohol consumption (>21 units/week) and/or a smoker (cigarettes or vaping)

10. Concomitant use of corticosteroids, antibiotics, any anabolic steroid, creatine, whey protein supplements, casein, branched-chain amino acids (BCAAs) or any other NHP [Natural Health Product], medication or supplement used for muscle strengthening/building within 45 days prior to screening

11. Contraindications to an MRI scan (metal implants, metal-based ink tattoo)

Related Conditions & MeSH terms

• Healthy
• Muscle Disuse Atrophy
• Muscular Disorders, Atrophic

Intervention

Dietary Supplement:
• Protein supplement
Ready-to-drink protein beverage consumed once daily for 28 days
• Protein supplement with Urolithin A
Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days

Locations

Country	Name	City	State
Canada	McMaster University	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
McMaster University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in maximal mitochondrial respiration (rate of oxygen flux) and mitochondrial ADP [adenosine diphosphate] sensitivity (Oroboros O2k)	Oxygen flux in muscle measured using Oroboros	Outcome measured and reported for: Day 7, Day 14, Day 28, Day 35
Secondary	Muscle strength (Biodex)	Isometric leg extension strength	Day 7, Day 14, Day 28, Day 35
Secondary	Quadriceps muscle size	Muscle size measured using MRI	Outcome measured and reported for: Day 14, Day 28, Day 35
Secondary	Muscle protein fractional synthetic rate	Protein synthetic rate using labelled alanine incorporation	Day 7, Day 14, Day 28, Day 35; integrated synthesis rates reported for Day 7-14, Day 14-28; Day 28-35